Home News & Events Events Events Filter events Filter events by clicking within the ‘Category’ drop-down list. Category - Any -IndustryWebinarsWorkshop Previous 1 2 In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media Related Information Webpage Webinars Webpage Industry Events Webpage Workshops What’s happening in ICON ICON Plc As oncology biologics face expiring patents, biosimilar developers need to prepare for a new era of opportunity and market growth. In this article, ICON’s Kim Salgado examines the opportunities and regulatory shifts th... 17h View post View webpage ICON Plc For AI biomarker discovery in oncology to move forward, developers must address several challenges. Find out what these are, and why AI is still positioned to transform the landscape of oncology therapeutics, in the arti... 22h 4 View post View webpage ICON Plc AI can find patterns in large datasets and detect complex relationships in patient data — making it a key tool for finding relevant oncology biomarkers. Read the article to discover how AI is being used in oncology bio... 22h View post View webpage ICON Plc Automation offers new opportunities to increase efficiency and reduce costs associated with post-marketing pharmacovigilance. Yet with patient safety at stake, the adoption of new technologies requires careful assessment... 17 Oct 2 View post View webpage ICON Plc The FDA and other health authorities like the EMA require a well-defined and consistent drug development process and life cycle management plan. CMC is a critical and a ‘first step’ component in the creation of a develop... 17 Oct View post View webpage ICON Plc Upstream and downstream process, structural characterisation, functional characterisation and processes are all major CMC related steps that need to be considered by emerging and biotech companies early in their developm... 17 Oct 2 View post View webpage ICON Plc Discover how GMP manufacturing can improve trial outcomes, reduce risk, and support regulatory success. During this webinar we will discuss the differences between GMP and USP compounding, and feature expert-led case stu... 17 Oct View post View webpage ICON Plc Day One of #ESMO2025 is drawing to a close. Thank you to everyone who has visited the ICON booth (\#3034) on Level 2, Hall 3.2 today. Our team of experts is available throughout the congress to discuss innovative appro... 17 Oct View post ICON Plc Impact assessments aren't just regulatory—they're strategic. In PharmaTimes, ICON’s Joanne Perry breaks down how sponsors and CROs can align on E6(R3) through cross-functional collaboration and dynamic planning. Read t... 17 Oct View post View webpage ICON Plc Wondering how to prepare for ICH GCP E6(R3)? Start with an impact assessment—it’s more than a checklist. It’s your roadmap to strategic compliance. Check out our latest article in PharmaTimes to learn how sponsors and CR... 17 Oct 2 View post View webpage ICON Plc Only 16% of surveyed oncology researchers reported using AI in biomarker detection and assessment at the time of the survey, but nearly half (49%) identified it as the area where AI and ML could most accelerate oncology ... 17 Oct View post View webpage ICON Plc Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv... 16 Oct 1 View post View webpage
